In the agreement with CoreValve, Medtronic will pay $700 million plus additional payments contingent on the achievement of agreed upon milestones. Medtronic will acquire Ventor for $325 million.
CoreValve is the developer of a transcatheter, transfemoral aortic valve replacement product. Ventor is the developer of two cardiovascular technologies — a minimally invasive, surgical transapical technology and a next-generation percutaneous, transfemoral technology.
Read the Medtronic news release on the acquisition of CoreValve.
Read the Medtronic news release on the acquisition of Ventor Technologies.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
